{"id":76636,"date":"2026-08-26T12:21:02","date_gmt":"2026-08-26T04:21:02","guid":{"rendered":"https:\/\/flcube.com\/?p=76636"},"modified":"2026-08-26T12:21:49","modified_gmt":"2026-08-26T04:21:49","slug":"gsks-jemperli-wins-fda-priority-review-for-dmmr-msi-h-locally-advanced-rectal-cancer-pdufa-date-set-for-february-2027","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76636","title":{"rendered":"GSK&#8217;s Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>GlaxoSmithKline Plc (GSK, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/GSK:NYSE\">NYSE: GSK<\/a>)<\/strong> announced that the <strong>US Food and Drug Administration (FDA)<\/strong> has accepted for <strong>priority review<\/strong> a supplemental Biologics License Application (sBLA) for <strong>Jemperli (dostarlimab)<\/strong> in patients with <strong>previously untreated stage II and III mismatch repair deficient (dMMR)\/microsatellite instability\u2011high (MSI\u2011H) locally advanced rectal cancer<\/strong>. The FDA assigned a <strong>PDUFA action date of February 2027<\/strong>, and the application is also eligible for expedited review through the <strong>National Priority Voucher program<\/strong>. <\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (US)<\/td><\/tr><tr><td><strong>Review Designation<\/strong><\/td><td>Priority review; eligible for National Priority Voucher expedited pathway<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Jemperli (dostarlimab), anti\u2011PD\u20111 monoclonal antibody<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Previously untreated stage II\/III dMMR\/MSI\u2011H locally advanced rectal cancer<\/td><\/tr><tr><td><strong>PDUFA Action Date<\/strong><\/td><td>February 2027<\/td><\/tr><tr><td><strong>Supporting Data<\/strong><\/td><td>Registrational Phase II AZUR\u20111 trial (single\u2011arm)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Jemperli (dostarlimab)<\/strong> \u2013 anti\u2011PD\u20111 monoclonal antibody<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks the PD\u20111 checkpoint pathway, restoring T\u2011cell\u2013mediated anti\u2011tumor immune responses<\/li>\n\n\n\n<li><strong>Indication Expansion:<\/strong> Move into the <strong>first\u2011line<\/strong> treatment of locally advanced rectal cancer<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Interim AZUR\u20111 data show tolerability generally consistent with Jemperli&#8217;s well\u2011characterised and manageable profile observed across solid tumours<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-azur-1-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 AZUR\u20111 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint \u2013 cCR12<\/strong><\/td><td>Met: meaningful and sustained clinical complete response rate at 12 months<\/td><\/tr><tr><td><strong>Durability<\/strong><\/td><td>No detectable signs of cancer for at least one year in responders<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Generally consistent with known, manageable PD\u20111 class profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The registrational Phase II single\u2011arm AZUR\u20111 study met its primary objective by demonstrating a sustained <strong>clinical complete response rate at 12 months (cCR12)<\/strong> \u2014 a result that, if confirmed, could support an organ\u2011preservation strategy and reduce reliance on surgery and radiation in this biomarker\u2011selected population.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> dMMR\/MSI\u2011H locally advanced rectal cancer has historically been managed with chemoradiation and surgery; a durable complete response opens a <strong>watch\u2011and\u2011wait, organ\u2011preserving<\/strong> treatment paradigm.<\/li>\n\n\n\n<li><strong>Regulatory Catalyst:<\/strong> A <strong>February 2027 PDUFA date<\/strong> provides a clear binary event for investors tracking GSK&#8217;s oncology pipeline monetisation.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> PD\u20111 blockade has shown outsized response rates in dMMR\/MSI\u2011H tumours versus standard approaches, a segment where immunotherapy holds a structural advantage.<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> A first\u2011line rectal cancer label would broaden Jemperli&#8217;s footprint alongside its existing endometrial cancer indications, strengthening GSK&#8217;s oncology franchise.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for Jemperli. Actual results may differ due to risks including final FDA review outcomes, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76640,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,4908],"tags":[278,184,914,18,80],"class_list":["post-76636","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-pic","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-pd-1-l1","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK&#039;s Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in patients with previously untreated stage II and III mismatch repair deficient (dMMR)\/microsatellite instability\u2011high (MSI\u2011H) locally advanced rectal cancer. The FDA assigned a PDUFA action date of February 2027, and the application is also eligible for expedited review through the National Priority Voucher program.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76636\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK&#039;s Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in patients with previously untreated stage II and III mismatch repair deficient (dMMR)\/microsatellite instability\u2011high (MSI\u2011H) locally advanced rectal cancer. The FDA assigned a PDUFA action date of February 2027, and the application is also eligible for expedited review through the National Priority Voucher program.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76636\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T04:21:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-26T04:21:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK&#8217;s Jemperli Wins FDA Priority Review for dMMR\\\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027\",\"datePublished\":\"2026-08-26T04:21:02+00:00\",\"dateModified\":\"2026-08-26T04:21:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636\"},\"wordCount\":435,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2601.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"PD-1\\\/L1\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76636#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76636\",\"name\":\"GSK's Jemperli Wins FDA Priority Review for dMMR\\\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2601.webp\",\"datePublished\":\"2026-08-26T04:21:02+00:00\",\"dateModified\":\"2026-08-26T04:21:49+00:00\",\"description\":\"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in patients with previously untreated stage II and III mismatch repair deficient (dMMR)\\\/microsatellite instability\u2011high (MSI\u2011H) locally advanced rectal cancer. The FDA assigned a PDUFA action date of February 2027, and the application is also eligible for expedited review through the National Priority Voucher program.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76636\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2601.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK's Jemperli Wins FDA Priority Review for dMMR\\\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76636#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK&#8217;s Jemperli Wins FDA Priority Review for dMMR\\\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027 - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in patients with previously untreated stage II and III mismatch repair deficient (dMMR)\/microsatellite instability\u2011high (MSI\u2011H) locally advanced rectal cancer. The FDA assigned a PDUFA action date of February 2027, and the application is also eligible for expedited review through the National Priority Voucher program.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76636","og_locale":"en_US","og_type":"article","og_title":"GSK's Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027","og_description":"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in patients with previously untreated stage II and III mismatch repair deficient (dMMR)\/microsatellite instability\u2011high (MSI\u2011H) locally advanced rectal cancer. The FDA assigned a PDUFA action date of February 2027, and the application is also eligible for expedited review through the National Priority Voucher program.","og_url":"https:\/\/flcube.com\/?p=76636","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-26T04:21:02+00:00","article_modified_time":"2026-08-26T04:21:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76636#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76636"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK&#8217;s Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027","datePublished":"2026-08-26T04:21:02+00:00","dateModified":"2026-08-26T04:21:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76636"},"wordCount":435,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76636#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2601.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK","PD-1\/L1","Priority reviews"],"articleSection":["Company","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76636#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76636","url":"https:\/\/flcube.com\/?p=76636","name":"GSK's Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76636#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76636#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2601.webp","datePublished":"2026-08-26T04:21:02+00:00","dateModified":"2026-08-26T04:21:49+00:00","description":"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in patients with previously untreated stage II and III mismatch repair deficient (dMMR)\/microsatellite instability\u2011high (MSI\u2011H) locally advanced rectal cancer. The FDA assigned a PDUFA action date of February 2027, and the application is also eligible for expedited review through the National Priority Voucher program.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76636#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76636"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76636#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2601.webp","width":1080,"height":608,"caption":"GSK's Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76636#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK&#8217;s Jemperli Wins FDA Priority Review for dMMR\/MSI\u2011H Locally Advanced Rectal Cancer \u2013 PDUFA Date Set for February 2027"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2601.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76636"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76636\/revisions"}],"predecessor-version":[{"id":76642,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76636\/revisions\/76642"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76640"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}